Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Moore (Stockley Park, United Kingdom), A. Preece (Stockley Park, United Kingdom), R. Sharma (Brentford, United Kingdom), L. Heaney (Northern Ireland, Ireland), R. Costello (Dublin, Ireland), R. Wise (Baltimore, United States of America), A. Ludwig-Sengpiel (Lübeck, Germany), G. Mosnaim (Evanston, Illinois, United States of America), J. Rees (Stockley Park, United Kingdom), R. Tomlinson (Upper Providence, Collegeville, Pennsylvania, United States of America), R. Tal-Singer (Upper Providence, Collegeville, Pennsylvania, United States of America), N. Barnes (Brentford; London , United Kingdom). Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma. 3561

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016 Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 ²Stepping down[/quot] from fluticasone propionate/salmeterol 100/50mcg Diskus® results in loss of asthma control Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Real world handling performance of fluticasone propionate/salmeterol HFA MDI with an integrated dose counter in subjects with asthma or COPD Source: Eur Respir J 2005; 26: Suppl. 49, 127s Year: 2005 Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013